ICD-10-PCS 2027 procedure code
XW033CAIntroduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
Short description: Introduce Zanidatamab in Periph Vein, Perc, New Tech 10
Code last changed in FY2025 (effective October 1, 2024). Source: official FY2027 ICD-10-PCS release from CMS. Page updated September 29, 2026. About our data
About XW033CA
XW033CA is the ICD-10-PCS code for a introduction procedure on the peripheral vein using a percutaneous approach with zanidatamab antineoplastic (qualifier: new technology group 10). In ICD-10-PCS, introduction means putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
For a different body part, codes include XW043CA (central vein).
With a different device, use XW0333A (maribavir anti-infective), XW0334A (stem cells, somatic), XW0335A (ifezuntirgene inilparvovec), XW0338A (mineral-based topical hemostatic agent), XW0339A (odronextamab antineoplastic), XW033BA (vancomycin-eluting bone void filler) and 4 more.
It doesn't appear in the MS-DRG procedure index, so on its own it doesn't change the DRG assignment.
It was added in FY2025, effective October 1, 2024.
What each character means
- 1. Section
- XNew Technology
- 2. Body System
- WAnatomical Regions
- 3. Operation
- 0Introduction
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
- 4. Body Part
- 3Peripheral Vein
- 5. Approach
- 3Percutaneous
Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure
- 6. Device / Substance / Technology
- CZanidatamab Antineoplastic
Includes: ZIIHERA(R)
- 7. Qualifier
- ANew Technology Group 10
Other versions of this procedure
Different body part
Different device / substance / technology
- XW0333AMaribavir Anti-infective
- XW0334AStem Cells, Somatic
- XW0335AIfezuntirgene Inilparvovec
- XW0338AMineral-based Topical Hemostatic Agent
- XW0339AOdronextamab Antineoplastic
- XW033BAVancomycin-eluting Bone Void Filler
- XW033DADonislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension
- XW033FAOther New Technology Therapeutic Substance
- XW033MABaricitinib
- XW033NASER-109
Different qualifier
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2025 (effective 10/1/2024): Added
- No changes since FY2025.
Common questions about XW033CA
Is XW033CA a valid ICD-10-PCS code for 2027?
- Yes. XW033CA is valid for inpatient procedures from October 1, 2026 through September 30, 2027.